The Spanish Agency of Medicines and Medical Devices (AEMPS) is the national authority responsible for ensuring the quality, safety, and efficacy of medicines and medical devices in Spain. Established to protect and promote public health, AEMPS oversees the evaluation, authorization, and monitoring of pharmaceutical products and medical devices. Engaging with AEMPS is essential for stakeholders aiming to navigate market access in the Spanish pharmaceutical landscape.
https://www.aemps.gob.es
Core Functions of AEMPS
AEMPS’ primary responsibilities include:- Authorization of Medicinal Products: Evaluating and granting marketing authorizations for new medicines to ensure they meet rigorous standards of quality, safety, and efficacy. administracion.gob.es
- Pharmacovigilance: Monitoring the safety of medicines post-marketing to promptly identify and manage adverse reactions.
- Regulation of Clinical Trials: Overseeing the authorization and conduct of clinical trials to ensure compliance with ethical and scientific standards. aemps.gob.es
- Control of Medical Devices and Cosmetics: Ensuring that medical devices and cosmetic products meet safety and performance requirements before they reach the market.
Leadership and Key Contacts
As of January 2025, AEMPS is led by Director María Jesús Lamas, who oversees the agency’s strategic initiatives and operations.Contact Details for AEMPS
Website: https://www.aemps.gob.es/ Postal Address: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) Calle Campezo, 1 28022 Madrid, Spain Telephone: +34 91 822 52 01Challenges in Working with AEMPS
Engaging with AEMPS involves:- Understanding Regulatory Procedures: Familiarity with AEMPS’ authorization processes and requirements is crucial for successful market access.
- Timely and Accurate Submissions: Ensuring that all necessary documentation is complete and submitted promptly to facilitate evaluation processes.
- Compliance with National and EU Regulations: Navigating the complex regulatory environment that includes both Spanish and European Union directives.
Opportunities / Solutions with Justin Stindt Consultants
Justin Stindt Consultants’ AEMPS expertise ensures:- Expert Consultant AEMPS Submissions: Creating high-quality submissions for marketing authorizations and clinical trial applications.
- Market Access AEMPS Strategies: Developing strategies that align with AEMPS’ regulatory framework to optimize market access.
- Specialist AEMPS Processes: Providing insights into AEMPS’ procedures to enhance compliance and expedite approvals.
Case Studies
A Pharmaceutical Company’s Success with AEMPS
Challenge:
A pharmaceutical company sought our assistance to obtain marketing authorization and reimbursement approval for a novel therapy in Spain.
Solution:
We guided them in preparing the needed documentation for AEMPS and a comprehensive value dossier that addressed the evaluators’ criteria.
Outcome:
Our strategic approach led to a positive outcome, enabling the obtention of the national code and the therapy’s inclusion in the national reimbursement list.
Need support with AEMPS market access? Justin Stindt Consultants has the expertise to help you succeed.
Contact us today to discuss your market access strategy and ensure your success with AEMPS.
Other Key Institutions in Market Access
Global Institutions
- World Health Organization (WHO)
- International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
United States
- Centers for Medicare & Medicaid Services (CMS)
- Academy of Managed Care Pharmacy (AMCP)
- Institute for Clinical and Economic Review (ICER)
France
Germany
- Gemeinsamer Bundesausschuss (G-BA)
- Institute for Quality and Efficiency in Health Care (IQWiG)
- GKV Spitzenverband
United-Kingdom
- National Institute for Health and Care Excellence (NICE)
- Scottish Medicines Consortium (SMC)
- All Wales Medicines Strategy Group (AWMSG)
- National Health Service (NHS)
Italy
Spain
- Spanish Agency of Medicines and Medical Devices (AEMPS)
- Dirección General de Cartera Común de Servicios del Sistema Nacional de Salud y Farmacia (DGCF)
- Interministerial Commission on Medicine Prices (CIPM)